Becton, Dickinson and Company (NYSE: BDX) is a global medical technology firm. It develops, makes, and sells a wide range of medical supplies, medical devices, and laboratory equipment. The company is known for its drug-delivery devices and surgical equipment, which are currently experiencing strong demand in the healthcare market.
On May 7, 2026, Becton, Dickinson and Company reported quarterly earnings of $2.90 per share, which beat analyst estimates of $2.77. As highlighted by Zacks, this figure is lower than the $3.35 per share reported in the same quarter last year. The company's Chairman, Tom Polen, described the quarter's performance as "solid."
The company also announced revenue of $4.71 billion, surpassing the consensus estimate of $4.67 billion. This represents a 5.2% increase in revenue for the second quarter of fiscal 2026, as reported by PR Newswire. This growth was attributed to strong performance across Becton, Dickinson and Company's various business platforms.
Citing strong demand, Becton, Dickinson and Company raised its annual profit forecast, as noted by Reuters. The company also took steps to improve its financial structure. It executed a $2 billion accelerated share repurchase program and retired $2.1 billion of its debt, signaling confidence in its financial health and future performance.
Becton, Dickinson and Company's financial metrics show a price-to-earnings (P/E) ratio of 35.70. This ratio indicates how much investors are willing to pay for each dollar of the company's earnings. Additionally, its debt-to-equity ratio is 0.31, suggesting that the company uses significantly more equity than debt to finance its assets.
